Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Kumamoto University
- Target Recruit Count
- 1000
- Registration Number
- NCT00140790
- Locations
- 🇯🇵
Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan
🇯🇵Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
A Morbidity-Mortality and Remodeling Study With Valsartan
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2005-10-28
- Lead Sponsor
- Jikei University School of Medicine
- Target Recruit Count
- 3000
- Registration Number
- NCT00133328
- Locations
- 🇯🇵
The Jikei University School of Medicine, Tokyo, Japan
Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
- Conditions
- Interventions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 1150
- Registration Number
- NCT00129233
- Locations
- 🇯🇵
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
Optimal Treatment for Kidney Disease in HIV Infected Adults
- Conditions
- Locations
- 🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States
🇺🇸Methodist Hospital of Indiana, Indianapolis, Indiana, United States
🇺🇸Wishard Hospital, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.